{"&cites=16172811975131816039&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1504627","authors":["J Brahmer","J Brahmer KL Reckamp","J Brahmer KL Reckamp P Baas","J Brahmer KL Reckamp P Baas L Crinò…"],"year":2015,"numCitations":5289,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1504627","citationUrl":"http://scholar.google.com/scholar?cites=18023613798475727448&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WIL5qkG9IPoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18023613798475727448&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596879364318},{"title":"PD-1 blockade in tumors with mismatch-repair deficiency","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1500596","authors":["DT Le","DT Le JN Uram","DT Le JN Uram H Wang","DT Le JN Uram H Wang BR Bartlett…"],"year":2015,"numCitations":4854,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1500596","citationUrl":"http://scholar.google.com/scholar?cites=10258601064941698851&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Iz9L8FDfXY4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10258601064941698851&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer","url":"https://science.sciencemag.org/content/348/6230/124.abstract","authors":["NA Rizvi","NA Rizvi MD Hellmann","NA Rizvi MD Hellmann A Snyder","NA Rizvi MD Hellmann A Snyder P Kvistborg…"],"year":2015,"numCitations":4359,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4993154/","citationUrl":"http://scholar.google.com/scholar?cites=6616874989748115658&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ylga177c01sJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6616874989748115658&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"},{"title":"Pembrolizumab for the treatment of non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","authors":["EB Garon","EB Garon NA Rizvi","EB Garon NA Rizvi R Hui","EB Garon NA Rizvi R Hui N Leighl…"],"year":2015,"numCitations":3642,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","citationUrl":"http://scholar.google.com/scholar?cites=4804110826968085903&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:j3UKB1ihq0IJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4804110826968085903&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673615012817","authors":["RS Herbst","RS Herbst P Baas","RS Herbst P Baas DW Kim","RS Herbst P Baas DW Kim E Felip","RS Herbst P Baas DW Kim E Felip JL Pérez"],"year":2016,"numCitations":3459,"pdf":"https://www.researchgate.net/profile/Marcelo_Garrido/publication/287505140_Pembrolizumab_versus_docetaxel_for_previously_treated_PD-L1-positive_advanced_non-small-cell_lung_cancer_KEYNOTE-010_A_randomised_controlled_trial/links/5cddf42d299bf14d959f721f/Pembrolizumab-versus-docetaxel-for-previously-treated-PD-L1-positive-advanced-non-small-cell-lung-cancer-KEYNOTE-010-A-randomised-controlled-trial.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10642977900179326521&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:OYaF5AJ0s5MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10642977900179326521&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"The future of immune checkpoint therapy","url":"https://science.sciencemag.org/content/348/6230/56.abstract","authors":["P Sharma","P Sharma JP Allison"],"year":2015,"numCitations":2228,"citationUrl":"http://scholar.google.com/scholar?cites=1385363128569161210&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:-uVJ62zMORMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1385363128569161210&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"},{"title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","url":"https://science.sciencemag.org/content/357/6349/409.abstract","authors":["DT Le","DT Le JN Durham","DT Le JN Durham KN Smith","DT Le JN Durham KN Smith H Wang…"],"year":2017,"numCitations":2146,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5576142/","citationUrl":"http://scholar.google.com/scholar?cites=17307069504521027125&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Nb74fwQQL_AJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17307069504521027125&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"},{"title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","url":"https://www.sciencedirect.com/science/article/pii/S014067361632517X","authors":["A Rittmeyer","A Rittmeyer F Barlesi","A Rittmeyer F Barlesi D Waterkamp","A Rittmeyer F Barlesi D Waterkamp K Park…"],"year":2017,"numCitations":2073,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6886121/","citationUrl":"http://scholar.google.com/scholar?cites=8337560628463052007&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:56TSoDf3tHMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8337560628463052007&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a …","url":"https://www.sciencedirect.com/science/article/pii/S0140673616005614","authors":["JE Rosenberg","JE Rosenberg J Hoffman"],"year":2016,"numCitations":2031,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242/","citationUrl":"http://scholar.google.com/scholar?cites=5432023266656526845&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:_SG4hGFsYksJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5432023266656526845&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","url":"https://www.sciencedirect.com/science/article/pii/S1535610815000896","authors":["SL Topalian","SL Topalian CG Drake","SL Topalian CG Drake DM Pardoll"],"year":2015,"numCitations":1983,"pdf":"https://www.sciencedirect.com/science/article/pii/S1535610815000896","citationUrl":"http://scholar.google.com/scholar?cites=762198590603665813&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:lSE8cZTfkwoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=762198590603665813&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"}]}